Core Viewpoint - The study identifies activated ATF6α as a hepatic tumor driver that limits immune surveillance, suggesting it as a potential stratification biomarker for immune checkpoint blockade (ICB) therapy response and a new therapeutic target for hepatocellular carcinoma (HCC) [3][11]. Group 1: Research Findings - Activated ATF6α is linked to aggressive tumor phenotypes in HCC, correlating with reduced patient survival rates, accelerated tumor progression, and local immune suppression [6]. - In mouse models, liver-specific activation of ATF6α leads to progressive hepatitis, characterized by endoplasmic reticulum (ER) stress, immune suppression, and hepatocyte proliferation [6]. - The activation of ATF6α enhances glycolysis and directly inhibits gluconeogenic enzyme FBP1, with restoration of FBP1 expression limiting pathological changes associated with ATF6α activation [6][9]. Group 2: Implications for Treatment - The study suggests that long-term activation of ATF6α induces ER stress, resulting in glycolysis-dependent immune suppression in HCC, making it sensitive to ICB therapy [9]. - In HCC patients, levels of ATF6α activation are significantly higher in those with complete responses to immunotherapy compared to those with weaker responses [7]. - Targeting Atf6 through germline knockout, liver-specific knockout, or delivering therapeutic antisense oligonucleotides (ASO) can suppress HCC in preclinical mouse models [8].

Core Viewpoint - The article discusses the role of the gut microbiome, specifically the bacterium Catenibacterium mitsuokai, in promoting hepatocellular carcinoma (HCC) through mechanisms involving gut barrier disruption and metabolic product secretion [2][3][5]. Group 1: Research Findings - A new carcinogenic gut bacterium, Catenibacterium mitsuokai, has been identified, which promotes the development of HCC by binding to hepatocytes and generating quinolinic acid [3][6]. - Catenibacterium mitsuokai is enriched in the feces and tumors of HCC patients, and it accelerates the carcinogenesis process in both conventional and germ-free mice [5][10]. - The bacterium disrupts the gut barrier and transfers to the liver, where it adheres to HCC cells via the interaction of its surface protein Gtr1/RagA with the γ-catenin receptor on cancer cells [6][10]. Group 2: Mechanistic Insights - The tumor-promoting effect of Catenibacterium mitsuokai is dependent on its secretion of the metabolite quinolinic acid [6][9]. - Quinolinic acid binds to the TIE2 receptor on HCC cells, activating the downstream oncogenic PI3K/AKT pathway, thereby facilitating the progression of liver cancer [6][9].

Core Viewpoint - The research identifies a class of micropeptides related to hepatocellular carcinoma (HCC) and reveals their regulatory mechanisms on mitochondrial RNA processing, providing new insights for cancer diagnosis and treatment [3][8]. Group 1: Research Findings - A new study published in Molecular Cell describes micropeptides associated with HCC and their role in modulating mitochondrial RNA processing machinery [3]. - The research team utilized a novel ultrafiltration tandem mass spectrometry method to identify a significant number of micropeptides in clinical HCC samples [4]. - One specific micropeptide, mitochondrial RNase P inhibitory peptide (MRPIP), derived from long non-coding RNA (lncRNA), inhibits the progression of HCC by regulating mitochondrial RNA processing [4][5]. Group 2: Mechanism of Action - MRPIP interacts with the R25 residue of HSD17B10, preventing the assembly of the mitochondrial RNase P (mtRNase P) complex, which disrupts HSD17B10 oligomerization and subsequent formation of the HSD17B10-TRMT10C subcomplex [5]. - This disruption leads to disturbances in post-transcriptional RNA processing, translation, and energy generation in mitochondria, thereby inhibiting cancer progression [5]. Group 3: Implications for Treatment - The research generated a functional peptide of 20 amino acids from the MRPIP sequence, which significantly inhibits the progression of HCC both in vitro and in vivo [6].